Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer

In brief

The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

Key facts

Study ID

NCT00345540

Run by

Cellectar Biosciences, Inc.

People needed

15

Starts

2006-07-01

Expected to finish

2008-06-01

Last updated by the study team

2015-03-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer
• ECOG 0-1
• Platinum resistant or refractory disease defined as progressive disease within 6 months of completing or while receiving their last platinum containing regimen
• Measurable disease

You may not qualify if…

• History of other malignancies within 2 years except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, incidental stage I endometrial cancer, basal or squamous cell skin cancer
• Major surgery within 2 weeks of study entry
• History of anaphylactic shock with prior platinum chemotherapy
• Known history of central nervous system (CNS) metastases unless subject has had treatment with surgery or radiation therapy and is neurologically stable
• Treatment with more than 3 lines of chemotherapy
• Chronic use of systemic corticosteroids

Where it is running

• Dana Farber Cancer/Partners Cancer Care — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.